Lv4
460 积分 2024-06-12 加入
Carvedilol as the new non‐selective beta‐blocker of choice in patients with cirrhosis and portal hypertension
10小时前
待确认
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial
10小时前
已完结
Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to β-blockers: A double-blind, placebo-controlled, randomized-trial
1天前
已完结
Two-year free of complications during antiviral therapy predicts stable re-compensation in immediate-treatment HBV-related decompensated cirrhosis
2天前
已完结
Recompensation in treatment-naïve HBV-related decompensated cirrhosis: a 5-year multi-center observational study comparing patients with ascites and bleeding
2天前
已完结
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)
2天前
已完结
Carvedilol versus endoscopic band ligation for secondary prophylaxis of variceal bleeding—long‐term follow‐up of a randomised control trial
2天前
已完结
Expanding consensus in portal hypertension
3天前
已完结
Preventing variceal rebleeding in cirrhotic patients with portal vein thrombosis: A systematic review and meta‐analysis
9天前
已完结
Predicting the 28-day prognosis of acute-on-chronic liver failure patients based on machine learning
15天前
已完结
皖公网安备34019202002308
